We have an experienced workforce and capabilities across our network to help you meet regulatory as well as Environment, Health and Safety (EHS) requirements for your next project. Our development and manufacturing site network is routinely inspected by global regulatory authorities including US FDA, EMA, MHRA & Swissmedic. Our cross-intercontinental sites in Visp (CH) and Nansha (CN) are approved for production of API and HPAPI for multiple markets.
Our broad capabilities and integrated approach enables you to use one partner throughout your project, from development through to manufacturing. This reduces risk, complexity and time to bring your HPAPI product to market. Our dedicated program management and experienced teams work together with you to ensure swift and efficient technology transfer and scale-up as required.
Very approachable, flexible and always informed about the status of ongoing activities to support the project. The Program Manager was also great at coordinating activities across multiple sites.
-Small Biotech, based in Europe
Advanced technology and innovation are core to our HPAPI approach, and investments remain core to our business. For example, we have developed and used continuous manufacturing to optimize production efficiency. This approach to innovation extends to our business models, which are highly flexible and designed to meet our customers’ specific requirements. Dedicated setups for HPAPI are just one example of how we can provide security of supply.
原薬（API）開発サービスのチームリーダー
Visp, Switzerland
Christian Notiは、スイスのVispにあるLonzaの医薬品製造サイトで、API開発サービスとHPAPI研究室のチームリーダーとして勤務しています。2008年、LonzaのResearch Chemistとして入社し、極めて複雑で化学上困難な複数の段階を経て合成する原薬の開発と技術移転を担当しました。過去7年間、高薬理活性な製品の開発とラボスケールの製造チームで、LonzaのHPAPI事業をさらに拡大する重要な役割を果たしてきました。